Dr. Richard D. Lopez is an Associate Professor of Medicine at Duke University and a physician-scientist specializing in hematologic malignancies and cellular therapy. After earning his medical degree and completing his fellowship at Stanford University, he focused his research on the clinical expansion of gamma/delta T-cells, a rare but potent subset of the immune system. As the Founder and CEO of PhosphoGam, Dr. Lopez transitioned his laboratory discoveries into a proprietary manufacturing platform. His technology enables an 80,000x expansion of T-cells, addressing the historical challenges of scalability and high production costs in immunotherapy. His work facilitates the development of "off-the-shelf" allogeneic therapies designed to be more accessible and safer for patients by eliminating the need for traditional viral vectors. Dr. Lopez’s career is defined by bridging the gap between academic research and commercial biotechnology. His current efforts at PhosphoGam focus on providing scalable, cost-effective cell therapies for both liquid and solid tumors, aiming to shift the standard of care toward mass-producible immunotherapy.